Ginkgo biloba and ovarian cancer prevention: Epidemiological and biological evidence

Cancer Letters

Volumn 251, Issue 1, 2007, Pages 43-52

  Ye, Bin ^a   Aponte, Margarita ^a   Dai, Yan ^b   Li, Lily ^c   Ho, Ming Chih D ^c   Vitonis, Allison ^a   Edwards, Dale ^a   Huang, Tai Nang ^c   Cramer, Daniel W ^a  

^a Epidemiology   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Linden Bioscience   (United States)

Author keywords

Cell biology; Cell proliferation; Epidemiology; Ginkgo; Ovarian cancer

Indexed keywords

CHONDROITIN; ECHINACEA EXTRACT; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINSENG EXTRACT; GLUCOSAMINE; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; KAEMPFEROL; QUERCETIN;

ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; EPIDEMIOLOGICAL DATA; FEMALE; GINKGO BILOBA; HERBAL MEDICINE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT;

CASE-CONTROL STUDIES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; CYSTADENOCARCINOMA, MUCINOUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GINKGO BILOBA; GINKGOLIDES; HUMANS; LACTONES; LOGISTIC MODELS; MASS SPECTROMETRY; MASSACHUSETTS; NEW HAMPSHIRE; OVARIAN NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; QUERCETIN;

GINKGO BILOBA;

EID: 34247249322     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.10.025     Document Type: Article

References (39)

1. Tesch B.J. Herbs commonly used by women: an evidence-based review. Am. J. Obstet. Gynecol. 188 (2003) S44-S55
2. DeFeudis F.V. A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry 36 Suppl. 1 (2003) S2-S7
3. Blume J., Kieser M., and Holscher U. Placebo-controlled double-blind study of the effectiveness of Ginkgo biloba special extract EGb 761 in trained patients with intermittent claudication. Vasa 25 (1996) 265-274
4. Schneider B. Ginkgo biloba extract in peripheral arterial diseases. Meta-analysis of controlled clinical studies. Arzneimittelforschung 42 (1992) 428-436
5. DeFeudis F.V., Papadopoulos V., and Drieu K. Ginkgo biloba extracts and cancer: a research area in its infancy. Fundam. Clin. Pharmacol. 17 (2003) 405-417
6. Alaoui-Youssefi A., Lamproglou I., Drieu K., and Emerit I. Anticlastogenic effects of Ginkgo biloba extract (EGb 761) and some of its constituents in irradiated rats. Mutat. Res. 445 (1999) 99-104
7. Emerit I., Oganesian N., Sarkisian T., Arutyunyan R., Pogosian A., Asrian K., Levy A., and Cernjavski L. Clastogenic factors in the plasma of Chernobyl accident recovery workers: anticlastogenic effect of Ginkgo biloba extract. Radiat. Res. 144 (1995) 198-205
8. Papadopoulos V., Kapsis A., Li H., Amri H., Hardwick M., Culty M., Kasprzyk P.G., Carlson M., Moreau J.P., and Drieu K. Drug-induced inhibition of the peripheral-type benzodiazepine receptor expression and cell proliferation in human breast cancer cells. Anticancer Res. 20 (2000) 2835-2847
9. Chao J.C., and Chu C.C. Effects of Ginkgo biloba extract on cell proliferation and cytotoxicity in human hepatocellular carcinoma cells. World J. Gastroenterol. 10 (2004) 37-41
10. Kim K.S., Rhee K.H., Yoon J.H., Lee J.G., Lee J.H., and Yoo J.B. Ginkgo biloba extract (EGb 761) induces apoptosis by the activation of caspase-3 in oral cavity cancer cells. Oral Oncol. 41 (2005) 383-389
11. Agha A.M., El-Fattah A.A., Al-Zuhair H.H., and Al-Rikabi A.C. Chemopreventive effect of Ginkgo biloba extract against benzo(a)pyrene-induced forestomach carcinogenesis in mice: amelioration of doxorubicin cardiotoxicity. J. Exp. Clin. Cancer Res. 20 (2001) 39-50
12. Tsao S.W., Mok S.C., Fey E.G., Fletcher J.A., Wan T.S., Chew E.C., Muto M.G., Knapp R.C., and Berkowitz R.S. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp. Cell Res. 218 (1995) 499-507
13. Bast Jr. R.C., Feeney M., Lazarus H., Nadler L.M., Colvin R.B., and Knapp R.C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68 (1981) 1331-1337
14. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
15. Plasencia C., Dayam R., Wang Q., Pinski J., Burke Jr. T.R., Quinn D.I., and Neamati N. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol. Cancer Ther. 4 (2005) 1105-1113
16. Cramer D.W., Kuper H., Harlow B.L., and Titus-Ernstoff L. Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women. Int. J. Cancer 94 (2001) 128-134
17. Kelly J.P., Kaufman D.W., Kelley K., Rosenberg L., Anderson T.E., and Mitchell A.A. Recent trends in use of herbal and other natural products. Arch. Intern. Med. 165 (2005) 281-286
18. Kobuchi H., Droy-Lefaix M.T., Christen Y., and Packer L. Ginkgo biloba extract (EGb 761): inhibitory effect on nitric oxide production in the macrophage cell line RAW 264.7. Biochem. Pharmacol. 53 (1997) 897-903
19. Gohil K., Moy R.K., Farzin S., Maguire J.J., and Packer L. mRNA expression profile of a human cancer cell line in response to Ginkgo biloba extract: induction of antioxidant response and the Golgi system. Free Radic. Res. 33 (2000) 831-849
20. Cheung F., Siow Y.L., and O K. Inhibition by ginkgolides and bilobalide of the production of nitric oxide in macrophages (THP-1) but not in endothelial cells (HUVEC). Biochem. Pharmacol. 61 (2001) 503-510
21. Juarez C.P., Muino J.C., Guglielmone H., Sambuelli R., Echenique J.R., Hernandez M., and Luna J.D. Experimental retinopathy of prematurity: angiostatic inhibition by nimodipine, ginkgo-biloba, and dipyridamole, and response to different growth factors. Eur. J. Ophthalmol. 10 (2000) 51-59
22. Monte M., Davel L.E., and de Lustig E.S. Inhibition of lymphocyte-induced angiogenesis by free radical scavengers. Free Radic. Biol. Med. 17 (1994) 259-266
23. Suzuki R., Kohno H., Sugie S., Sasaki K., Yoshimura T., Wada K., and Tanaka T. Preventive effects of extract of leaves of ginkgo (Ginkgo biloba) and its component bilobalide on azoxymethane-induced colonic aberrant crypt foci in rats. Cancer Lett. 210 (2004) 159-169
24. Wei E.H., Rao M.R., Ji N.D., Chen X.Y., and Chen Q. Inhibitory effects of ginkgolide B on proliferation of bovine aortic smooth muscle cells. Yao Xue Xue Bao 37 (2002) 90-93
25. Pisano C., Greggi S., Tambaro R., Losito S., Iodice F., Di Maio M., Ferrari E., Falanga M., Formato R., Iaffaioli V.R., and Pignata S. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study. Anticancer Res. 25 (2005) 3501-3505
26. Pectasides D., Fountzilas G., Aravantinos G., Kalofonos H.P., Efstathiou E., Salamalekis E., Farmakis D., Skarlos D., Briasoulis E., Economopoulos T., and Dimopoulos M.A. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol. Oncol. 97 (2005) 436-441
27. Wang V., Li C., Lin M., Welch W., Bell D., Wong Y.F., Berkowitz R., Mok S.C., and Bandera C.A. Ovarian cancer is a heterogeneous disease. Cancer Genet. Cytogenet. 161 (2005) 170-173
28. Wamunyokoli F.W., Bonome T., Lee J.Y., Feltmate C.M., Welch W.R., Radonovich M., Pise-Masison C., Brady J., Hao K., Berkowitz R.S., Mok S., and Birrer M.J. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin. Cancer Res. 12 (2006) 690-700
29. Li W., Shen F., and Weber G. Ribavirin and quercetin synergistically downregulate signal transduction and are cytotoxic in human ovarian carcinoma cells. Oncol. Res. 11 (1999) 243-247
30. Scambia G., Panici P.B., Ranelletti F.O., Ferrandina G., De Vincenzo R., Piantelli M., Masciullo V., Bonanno G., Isola G., and Mancuso S. Quercetin enhances transforming growth factor beta 1 secretion by human ovarian cancer cells. Int. J. Cancer 57 (1994) 211-215
31. Wang H.K. The therapeutic potential of flavonoids. Expert Opin. Investig. Drugs 9 (2000) 2103-2119
32. Lamson D.W., and Brignall M.S. Antioxidants and cancer, part 3: quercetin. Altern. Med. Rev. 5 (2000) 196-208
33. Graefe E.U., Derendorf H., and Veit M. Pharmacokinetics and bioavailability of the flavonol quercetin in humans. Int. J. Clin. Pharmacol. Ther. 37 (1999) 219-233
34. Gregory R.E., and DeLisa A.F. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin. Pharm. 12 (1993) 401-415
35. Ravelo A.G., Estevez-Braun A., Chavez-Orellana H., Perez-Sacau E., and Mesa-Siverio D. Recent studies on natural products as anticancer agents. Curr. Top. Med. Chem. 4 (2004) 241-265
36. Molnar J., Gyemant N., Tanaka M., Hohmann J., Bergmann-Leitner E., Molnar P., Deli J., Didiziapetris R., and Ferreira M.J. Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. Curr. Pharm. Des. 12 (2006) 287-311
37. Stadheim T.A., Suh N., Ganju N., Sporn M.B., and Eastman A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J. Biol. Chem. 277 (2002) 16448-16455
38. Fourtillan J.B., Brisson A.M., Girault J., Ingrand I., Decourt J.P., Drieu K., Jouenne P., and Biber A. Pharmacokinetic properties of Bilobalide and Ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761). Therapie 50 (1995) 137-144
39. Cellai C., Laurenzana A., Vannucchi A.M., Caporale R., Paglierani M., Di Lollo S., Pancrazzi A., and Paoletti F. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086. Br. J. Cancer 94 (2006) 1637-1642